Longeveron Inc. announced that it has been featured in a broadcast via NetworkNewsAudio ("NNA"), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers Longeveron's recent announcement of positive top-line results from its Phase 2a trial of its investigational product Lomecel-B?? for the treatment of mild Alzheimer's disease.

The study safety data were consistent with an established safety profile with no incidence of hypersensitivity, no cases of Alzheimer Related Imagine Abnormalities (ARIA), no clinically asmptomatic microhemorrhages as revealed by Magnetic Resonance Imaging (MRI), and no notable changes in laboratory evaluations and electrocardiogram (EKG).